CDC gives Prevnar 13 the cold shoulder for over-50s

Share this article:
Pfizer Prevnar data could boost Rx numbers
Pfizer Prevnar data could boost Rx numbers
Despite a fast-tracked FDA approval, the Centers for Disease Control is holding off on endorsing pneumonia vaccine Prevnar 13 for adults 50 and over pending results of a study not due to wind down until next year.

The CDC already endorses the Pfizer drug for children, but said Wednesday it wants to see the results of a study being conducted in the Netherlands before backing the drug's use among a broader population. Results on that study are expected next year. FDA approved the vaccine for use in adults 50 and over in December.

The CDC's advisory council currently endorses Merck's Pneumovax for adults who are at least 65, and it is approved for the over-50 set. Pfizer's Prevnar 13 protects against 13 serotypes, one of which is not covered by Merck's Pneumovax.

Although the 84,000-person study the CDC is waiting on won't be finished until next year, Pfizer isn't holding back. It said in a statement that it will go ahead with its plans to market Prevnar 13 as an adult vaccine over the next few weeks. The company said it does not expect the CDC's reservations to affect its sales outlook.

CDC data estimates that pneumococcal pneumonia kills about 5% to 7% of infected patients, with a higher percentage among the elderly, and the FDA estimates the disease hospitalizes 300,000 adults in the 50-plus age range every year.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...